Albert Labs International Corp.
Albert Labs International Corp.

Albert Labs International Corp. is a clinical research and laboratory-based drug development company serving the needs of mental health care. Through a succinct, real-world evidence (RWE)-driven clinical journey, Albert Labs seeks to commercialize its psychedelic-based treatments and, in doing so, bring psychedelic-assisted psychotherapy to patients sooner. Focused on accelerating access and faster approvals, Albert Labs prioritizes patients with urgent and unmet needs by developing licensed drugs to treat a variety of mental health conditions. Cancer-related distress, an original goal of Albert Labs' development program, is thought to affect more than 16 million patients worldwide.
Albert Labs International Corp. (ABRT)
SEDAR Information
Information d'entreprise
Capitalisation
Communiqués de presse
Bulletins
2023-0707 - Réintégration – Albert Labs International Corp. (ABRT)
le 7 juillet/July 2023
Effective immediately, Albert Labs International Corp. will be reinstated for trading.
The Company has rectified the situation that gave rise to the suspension.
____________________________